Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Genpathway to Offer ChIP Sequencing, Assays and Analysis Service

NEW YORK (GenomeWeb News) – Illumina and Genpathway have partnered to offer scientists a solution for studying transcription factor binding and gene regulation in drug development research, Illumina said today.
 
Under the partnership, Genpathway will prepare samples using its FactorPath ChIP assays and will conduct data analysis using its software. The sequencing will be handled by Illumina’s Sequencing Services, which will employ the firm’s high-throughput Genome Analyzer, the company said.
 
The combined services the companies plan to offer include cell or tissue processing, antibody selection and qualification, and ChIP DNA amplification, Illumina said.
 
Because ChIP sequencing is “a notoriously time-consuming and difficult procedure,” Genpathway CSO Mary Harper said in a statement, the partnership will allow the companies to offer scientists “a faster path to discovery.”

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.